<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01135329</url>
  </required_header>
  <id_info>
    <org_study_id>J1046</org_study_id>
    <secondary_id>NA_00039363</secondary_id>
    <nct_id>NCT01135329</nct_id>
  </id_info>
  <brief_title>Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers</brief_title>
  <official_title>Reduced-intensity, Related-donor Allogeneic BMT With Fludarabine, Busulfan, and High-dose Posttransplantation Cyclophosphamide for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to learn more about reduced-intensity bone marrow transplantation
      (BMT), also known as a &quot;mini&quot; transplant for patients with blood cancers, using bone marrow
      from a relative.

      The main goal of the study is to determine how quickly the donor's bone marrow &quot;takes&quot; in
      your body. Other goals include describing how many people accept the bone marrow and how
      quickly the blood counts come up; describing Graft-versus-host disease (GVHD) and other
      complications; and describing how many people survive without progressive cancer and survive
      overall
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the present time there are few or no cures for people with cancer of the blood or lymph
      glands outside of a bone marrow transplant (BMT). BMT has developed over several decades of
      research as an effective treatment of various malignant and nonmalignant hematologic
      diseases.

      This research is being done to learn more about reduced-intensity bone marrow transplantation
      (BMT), also known as a &quot;mini&quot; transplant for patients with blood cancers, using bone marrow
      from a relative. The bone marrow for this transplant comes from a relative who is a
      half-match or &quot;haplo&quot; match to you. Possible donors include parents, siblings, and children.

      &quot;Mini&quot; transplants have been given to many people with various cancers but are considered
      experimental. Over 200 people at Johns Hopkins have received mini transplants with high doses
      of cyclophosphamide after the transplant. However, the chemotherapy combination and other
      treatment given before those transplants were different from what is in this study. Although
      all of the chemotherapy and immune-lowering drugs used in this study are approved by the Food
      and Drug Administration (FDA), the combination of medications used in this study are not FDA
      approved and are experimental.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The stopping rule was met and hence the study was closed
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chimerism in Unsorted Peripheral Blood</measure>
    <time_frame>Day 60</time_frame>
    <description>Percentage of participants achieving full-donor chimerism in unsorted peripheral blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chimerism in CD3+ Sorted Peripheral Blood</measure>
    <time_frame>Day 60</time_frame>
    <description>Percentage of participants achieving full-donor chimerism in CD3+ sorted peripheral blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants alive without disease relapse or progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Relapse</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants experiencing disease relapse or progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants who died due to BMT-related reasons</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Graft-versus-host-disease (GVHD)</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of participants experiencing acute and chronic GVHD. Acute GVHD is graded by Przepiorka criteria. Chronic GVHD is graded by NIH consensus criteria and Seattle criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Failure</measure>
    <time_frame>Day 60</time_frame>
    <description>Percentage of participants who failed to engraft.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Lymphoma</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m^2 IV daily on Day -6 through Day -2.</description>
    <arm_group_label>Transplant</arm_group_label>
    <other_name>Fludara</other_name>
    <other_name>Flu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>1 mg/kg PO OR 0.8 mg/kg IV four times daily on Day -6 through Day -3.</description>
    <arm_group_label>Transplant</arm_group_label>
    <other_name>Busulfex</other_name>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>50 mg/kg IV daily on Day +3 and Day +4.</description>
    <arm_group_label>Transplant</arm_group_label>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Cy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>15 mg/kg PO three times daily (max daily dose of 3g) starting on Day +5.</description>
    <arm_group_label>Transplant</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Dosed based on drug levels; begin on Day +5 at 1 mg IV daily.</description>
    <arm_group_label>Transplant</arm_group_label>
    <other_name>FK506</other_name>
    <other_name>FK-506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First-degree related donor who is at minimum HLA haploidentical

          -  Eligible diagnoses:

               1. Low-grade non-Hodgkin's lymphoma or plasma cell neoplasm that has progressed
                  during multiagent therapy, failed at least two prior therapies (excluding single
                  agent rituximab and single agent steroids), or in the case of lymphoma undergone
                  histological conversion:

                    -  Follicular grade 1 or 2 lymphoma

                    -  Follicular lymphoma not otherwise specified

                    -  Marginal zone (or MALT) lymphoma

                    -  Lymphoplasmacytic lymphoma / Waldenstrom's macroglobulinemia

                    -  Hairy cell leukemia

                    -  Small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL)

                    -  Prolymphocytic leukemia

                    -  Low grade B-cell lymphoma, unspecified

                    -  Multiple myeloma

                    -  Plasma cell leukemia

               2. Poor-risk SLL or CLL, defined by an 11q or 17p deletion, histological conversion,
                  or disease progression &lt; 6 months after a purine analog-containing regimen

               3. Aggressive lymphoma that has failed at least one prior regimen of multiagent
                  chemotherapy, and patient is either ineligible for autologous BMT or autologous
                  BMT is not recommended:

                    -  Hodgkin lymphoma

                    -  Follicular grade 3 lymphoma

                    -  Mantle cell lymphoma or leukemia

                    -  Diffuse large B-cell lymphoma (excluding primary CNS lymphoma). Eligible
                       subtypes include primary mediastinal large B-cell lymphoma, T-cell rich
                       large B-cell lymphoma, and large B-cell lymphoma not otherwise specified.

                    -  Burkitt's lymphoma/leukemia

                    -  Atypical Burkitt's lymphoma/leukemia (high grade B-cell lymphoma,
                       unclassified, including that with features intermediate between Burkitt's
                       and diffuse large B-cell lymphoma)

                    -  Anaplastic large cell lymphoma

                    -  Plasmablastic lymphoma

                    -  Peripheral T-cell lymphoma

               4. Relapsed or refractory acute leukemia in second or subsequent remission

               5. Poor-risk acute leukemia in first remission

               6. AML with at least one of the following:

                    -  AML arising from MDS or a myeloproliferative disorder, or secondary AML

                    -  Presence of Flt3 internal tandem duplications

                    -  Poor-risk cytogenetics

                    -  Primary refractory disease

                         -  ALL (leukemia and/or lymphoma) with at least one of the following:

                    -  Adverse cytogenetics

                    -  Clear evidence of hypodiploidy

                    -  Primary refractory disease

                         -  Biphenotypic leukemia

                         -  MDS with at least one of the following features:

                         -  Poor-risk cytogenetics

                         -  IPSS score of INT-2 or greater

                         -  Treatment-related MDS

                         -  MDS diagnosed before age 21 years

                         -  Progression on or lack of response to standard DNA-methyltransferase
                            inhibitor therapy

                         -  Life-threatening cytopenias, including those generally requiring
                            greater than weekly transfusions

               7. Interferon- or imatinib-refractory CML in first chronic phase, or non-blast
                  crisis CML beyond first chronic phase

               8. Philadelphia chromosome negative myeloproliferative disease (including
                  myelofibrosis)

               9. Chronic myelomonocytic leukemia

              10. Juvenile myelomonocytic leukemia

                    -  For patients with SLL, CLL, or prolymphocytic leukemia, &lt; 20% of bone marrow
                       cellularity involved by this process

                    -  Adequate end-organ function:

          -  Left ventricular ejection fraction greater than or equal to 35%

          -  Bilirubin â‰¤ 3.0 mg/dL (unless due to Gilbert's syndrome or hemolysis), and ALT and AST
             &lt; 5 x ULN

          -  FEV1 and FVC &gt; 40% of predicted; or in pediatric patients, if unable to perform
             pulmonary function tests due to young age, oxygen saturation &gt;92% on room air

               -  ECOG performance status &lt; 2 or Karnofsky or Lansky score &gt; 60

        Exclusion Criteria:

          -  Pregnant or breast-feeding

          -  Uncontrolled infection Note: Infection is permitted if there is evidence of response
             to medication. Eligibility of HIV infected patients will be determined on a
             case-by-case basis.

          -  Any previous BMT within 3 months prior to start of conditioning

          -  Active extra-medullary leukemia or known active Central Nervous System (CNS)
             involvement by malignancy. Such disease treated into remission is permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvette Kasamon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Sydney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 1, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <results_first_submitted>August 22, 2014</results_first_submitted>
  <results_first_submitted_qc>June 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 3, 2018</results_first_posted>
  <last_update_submitted>June 29, 2018</last_update_submitted>
  <last_update_submitted_qc>June 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Hodgkin's lymphoma</keyword>
  <keyword>Non hodgkin's lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Acute myeloid leukemia (AML)</keyword>
  <keyword>Acute lymphoblastic leukemia(ALL)</keyword>
  <keyword>Chronic myeloid leukemia (CML)</keyword>
  <keyword>Chronic Myelomonocytic (CMML)</keyword>
  <keyword>Myelodysplastic syndrome (MDS)</keyword>
  <keyword>High-risk acute leukemia in first remission</keyword>
  <keyword>Relapsed leukemia in remission</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>High-dose cyclophosphamide</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Nonmyeloablative</keyword>
  <keyword>Reduced intensity</keyword>
  <keyword>Haploidentical</keyword>
  <keyword>Bone marrow transplant (BMT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BMT Allogenic Transplantation</title>
          <description>Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus,: Fludarabine 30 mg/m2 IV once a day for 4 days Busulfan 0.8 mg/kg IV every 12 hours for 4 days Cyclophosphamide 50 mg/kg IV daily for 2 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BMT Allogenic Transplantation</title>
          <description>Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus,: Fludarabine 30 mg/m2 IV once a day for 4 days Busulfan 0.8 mg/kg IV every 12 hours for 4 days Cyclophosphamide 50 mg/kg IV daily for 2 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="3" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Chimerism in Unsorted Peripheral Blood</title>
        <description>Percentage of participants achieving full-donor chimerism in unsorted peripheral blood.</description>
        <time_frame>Day 60</time_frame>
        <population>The trial has been terminated early since stopping rule criteria were met (high graft failure rate). Data were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>BMT Allogenic Transplantation</title>
            <description>Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.</description>
          </group>
        </group_list>
        <measure>
          <title>Chimerism in Unsorted Peripheral Blood</title>
          <description>Percentage of participants achieving full-donor chimerism in unsorted peripheral blood.</description>
          <population>The trial has been terminated early since stopping rule criteria were met (high graft failure rate). Data were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Chimerism in CD3+ Sorted Peripheral Blood</title>
        <description>Percentage of participants achieving full-donor chimerism in CD3+ sorted peripheral blood</description>
        <time_frame>Day 60</time_frame>
        <population>The trial has been terminated early since stopping rule criteria were met (high graft failure rate). Data were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>BMT Allogenic Transplantation</title>
            <description>Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.</description>
          </group>
        </group_list>
        <measure>
          <title>Chimerism in CD3+ Sorted Peripheral Blood</title>
          <description>Percentage of participants achieving full-donor chimerism in CD3+ sorted peripheral blood</description>
          <population>The trial has been terminated early since stopping rule criteria were met (high graft failure rate). Data were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Percentage of participants alive</description>
        <time_frame>1 year</time_frame>
        <population>The trial has been terminated early since stopping rule criteria were met (high graft failure rate). Data were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>BMT Allogenic Transplantation</title>
            <description>Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Percentage of participants alive</description>
          <population>The trial has been terminated early since stopping rule criteria were met (high graft failure rate). Data were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Percentage of participants alive without disease relapse or progression.</description>
        <time_frame>1 year</time_frame>
        <population>The trial has been terminated early since stopping rule criteria were met (high graft failure rate). Data were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>BMT Allogenic Transplantation</title>
            <description>Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Percentage of participants alive without disease relapse or progression.</description>
          <population>The trial has been terminated early since stopping rule criteria were met (high graft failure rate). Data were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Relapse</title>
        <description>Percentage of participants experiencing disease relapse or progression</description>
        <time_frame>1 year</time_frame>
        <population>The trial has been terminated early since stopping rule criteria were met (high graft failure rate). Data were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>BMT Allogenic Transplantation</title>
            <description>Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Relapse</title>
          <description>Percentage of participants experiencing disease relapse or progression</description>
          <population>The trial has been terminated early since stopping rule criteria were met (high graft failure rate). Data were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-relapse Mortality</title>
        <description>Percentage of participants who died due to BMT-related reasons</description>
        <time_frame>1 year</time_frame>
        <population>The trial has been terminated early since stopping rule criteria were met (high graft failure rate). Data were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>BMT Allogenic Transplantation</title>
            <description>Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality</title>
          <description>Percentage of participants who died due to BMT-related reasons</description>
          <population>The trial has been terminated early since stopping rule criteria were met (high graft failure rate). Data were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Graft-versus-host-disease (GVHD)</title>
        <description>Percentage of participants experiencing acute and chronic GVHD. Acute GVHD is graded by Przepiorka criteria. Chronic GVHD is graded by NIH consensus criteria and Seattle criteria.</description>
        <time_frame>1 year</time_frame>
        <population>The trial has been terminated early since stopping rule criteria were met (high graft failure rate). Data were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Transplant</title>
            <description>Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Graft-versus-host-disease (GVHD)</title>
          <description>Percentage of participants experiencing acute and chronic GVHD. Acute GVHD is graded by Przepiorka criteria. Chronic GVHD is graded by NIH consensus criteria and Seattle criteria.</description>
          <population>The trial has been terminated early since stopping rule criteria were met (high graft failure rate). Data were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Failure</title>
        <description>Percentage of participants who failed to engraft.</description>
        <time_frame>Day 60</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transplant</title>
            <description>Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Failure</title>
          <description>Percentage of participants who failed to engraft.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Data was collected systematically through at least Day 60 by investigator assessment at protocol-specified visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>Transplant</title>
          <description>Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated liver enzymes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Elevated total bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>hallucinations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yvette Kasamon</name_or_title>
      <organization>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</organization>
      <phone>410-955-8839</phone>
      <email>ykasamo1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

